News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
News provided by Provectus Biopharmaceuticals Inc. Dec 01, 2022, 7:00 AM ET 50% CR and 83% ORR by RECIST 1.1 criteria Rapid CRs…
50% CR and 83% ORR by RECIST 1.1 criteria Rapid CRs achieved within 15 to 27 weeks Median PFS not reached during 2-year…
50% CR and 83% ORR by RECIST 1.1 criteria Rapid CRs achieved within 15 to 27 weeks Median PFS not reached during 2-year…
50% CR and 83% ORR by RECIST 1.1 criteria Rapid CRs achieved within 15 to 27 weeks Median PFS not reached during 2-year…
50% CR and 83% ORR by RECIST 1.1 criteria Rapid CRs achieved within 15 to 27 weeks Median PFS not reached during 2-year…
GlobeNewswire 2022-12-01 50% CR and 83% ORR by RECIST 1.1 criteria Rapid CRs achieved within 15 to 27 weeks Median PFS not…
50% CR and 83% ORR by RECIST 1.1 criteria Rapid CRs achieved within 15 to 27 weeks Median PFS not reached during 2-year…
50% CR and 83% ORR by RECIST 1.1 criteria Rapid CRs achieved within 15 to 27 weeks Median PFS not reached during 2-year…
50% CR and 83% ORR by RECIST 1.1 criteria Rapid CRs achieved within 15 to 27 weeks Median PFS not reached during 2-year…
50% CR and 83% ORR by RECIST 1.1 criteria Rapid CRs achieved within 15 to 27 weeks Median PFS not reached during 2-year…
50% CR and 83% ORR by RECIST 1.1 criteria Rapid CRs achieved within 15 to 27 weeks Median PFS not reached during 2-year…
50% CR and 83% ORR by RECIST 1.1 criteria Rapid CRs achieved within 15 to 27 weeks Median PFS not reached during 2-year…
50% CR and 83% ORR by RECIST 1.1 criteria Rapid CRs achieved within 15 to 27 weeks Median PFS not reached during 2-year…
50% CR and 83% ORR by RECIST 1.1 criteria Rapid CRs achieved within 15 to 27 weeks Median PFS not reached during 2-year…
GlobeNewswire 2021-07-19 KNOXVILLE, TN, July 19, 2021 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data…
KNOXVILLE, TN, July 19, 2021 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from an ongoing clinical…
KNOXVILLE, TN, July 19, 2021 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from an ongoing clinical…
In this article: KNOXVILLE, TN, July 19, 2021 Provectus (OTCQB: PVCT) today announced that data from an ongoing clinical trial…
KNOXVILLE, TN, July 19, 2021 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from an ongoing clinical…
— PV-10 treatment induced autophagic cell death in all breast, colorectal, head and neck, and testicular cancer cell lines…
GlobeNewswire 2021-06-09 — PV-10 treatment induced autophagic cell death in all breast, colorectal, head and neck, and…
— PV-10 treatment induced autophagic cell death in all breast, colorectal, head and neck, and testicular cancer cell lines…
— PV-10 treatment induced autophagic cell death in all breast, colorectal, head and neck, and testicular cancer cell lines…
— PV-10 treatment induced autophagic cell death in all breast, colorectal, head and neck, and testicular cancer cell lines…
— PV-10 treatment induced autophagic cell death in all breast, colorectal, head and neck, and testicular cancer cell lines…
— PV-10 treatment induced autophagic cell death in all breast, colorectal, head and neck, and testicular cancer cell lines…
— Systemic disease control achieved in heavily pre-treated liver cancer patients — 83% DCR; median PFS of 9.2 months; median OS…
Secondary endpoints include ORR of injected target and measurable bystander lesions, target lesion somatostatin receptor…
— Systemic disease control achieved in heavily pre-treated liver cancer patients — 83% DCR; median PFS of 9.2 months; median OS…
IL PV-10 has been administered to over 450 patients with cancers of the skin and of the liver.
— Intralesional (aka intratumoral) PV-10 administration for treatment of hepatic metastatic neuroendocrine tumors (NCT02693067) …
— Intralesional (aka intratumoral) PV-10 administration for treatment of hepatic metastatic neuroendocrine tumors ( NCT02693 0…
— Intralesional (aka intratumoral) PV-10 administration for treatment of hepatic metastatic neuroendocrine tumors (NCT02693067…
— Intralesional (aka intratumoral) PV-10 administration for treatment of hepatic metastatic neuroendocrine tumors (NCT0269367) …
— Intralesional (aka intratumoral) PV-10 administration for treatment of hepatic metastatic neuroendocrine tumors ( NCT02693 0…
— Intralesional (aka intratumoral) PV-10 administration for treatment of hepatic metastatic neuroendocrine tumors ( NCT02693 0…
GlobeNewswire Provectus Biopharmaceuticals Announces Acceptance of PV-10® Immunotherapy Abstracts at American Society of…
GlobeNewswire Provectus Biopharmaceuticals Announces Acceptance of PV-10® Immunotherapy Abstracts at American Society of…
— Intralesional (aka intratumoral) PV-10 administration for treatment of hepatic metastatic neuroendocrine tumors () — Systemic…
— Intralesional (aka intratumoral) PV-10 administration for treatment of hepatic metastatic neuroendocrine tumors ( NCT02693 0…
— Intralesional (aka intratumoral) PV-10 administration for treatment of hepatic metastatic neuroendocrine tumors () — Systemic…
— Intralesional (aka intratumoral) PV-10 administration for treatment of hepatic metastatic neuroendocrine tumors (NCT02693067) …
— Intralesional (aka intratumoral) PV-10 administration for treatment of hepatic metastatic neuroendocrine tumors () — Systemic…
— Intralesional (aka intratumoral) PV-10 administration for treatment of hepatic metastatic neuroendocrine tumors ( NCT02693 0…
— Intralesional (aka intratumoral) PV-10 administration for treatment of hepatic metastatic neuroendocrine tumors ( NCT02693 0…
The non-clinical results presented at this years annual meeting of the Society for Immunotherapy of Cancer demonstrate that…
KNOXVILLE, TN, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that H.
KNOXVILLE, TN, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that H.
KNOXVILLE, TN, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that H.
KNOXVILLE, TN, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that H.
KNOXVILLE, TN, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that H.
KNOXVILLE, TN, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that H.
KNOXVILLE, TN, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that H.
KNOXVILLE, TN, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that H.
KNOXVILLE, TN, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that H.
KNOXVILLE, TN, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from the Company's ongoing…
KNOXVILLE, TN, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from the Company's ongoing…
KNOXVILLE, TN, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from the Company's ongoing…
KNOXVILLE, TN, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from the Company's ongoing…
KNOXVILLE, TN, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from the Company's ongoing…
KNOXVILLE - Provectus (OTCQB: PVCT) today announced that will present non-clinical data from ongoing research on…
RBD selectively accumulates in the lysosomes of cancer cells upon contact, disrupts these lysosomes, and causes the cells to die.
KNOXVILLE, TN, Oct. 15, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that H.
KNOXVILLE, TN, Oct. 15, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that H.
KNOXVILLE, TN, Oct. 15, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that H.
KNOXVILLE, TN, Oct. 15, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that H.
UCalgary showed that PV-10 treatment led to STING dimerization and the release of interferon gamma (IFN), indicating a…
PV-10 treatment leads to STING dimerization Researchers identify potential association of heat shock proteins with STING in PV-10…
PV-10 treatment leads to STING dimerization Researchers identify potential association of heat shock proteins with STING in PV-10…
PV-10 treatment leads to STING dimerization Researchers identify potential association of heat shock proteins with STING in PV-10…
PV-10 treatment leads to STING dimerization Researchers identify potential association of heat shock proteins with STING in PV-10…
PV-10 treatment leads to STING dimerization Researchers identify potential association of heat shock proteins with STING in PV-10…
PV-10 treatment leads to STING dimerization Researchers identify potential association of heat shock proteins with STING in PV-10…
PV-10 treatment leads to STING dimerization Researchers identify potential association of heat shock proteins with STING in PV-10…
Provectus further expands cancer combination therapy IP protection by filing new USPTO patent application for immunotherapy…
2020 India patent follows 2018 India patent that protects Provectus’ proprietary API manufacturing process Provectus further…
2020 India patent follows 2018 India patent that protects Provectus’ proprietary API manufacturing process Provectus further…
2020 India patent follows 2018 India patent that protects Provectus’ proprietary API manufacturing process Provectus further…
Response assessments using European Association of the Study of the Liver (2D-EASL) criteria are performed at Day 28, and then…
Treatment refractory, immunologically cold, hepatic tumor type 37% reduction and 83% stabilization of treated disease (2D-EASL…
Treatment refractory, immunologically cold, hepatic tumor type 37% reduction and 83% stabilization of treated disease (2D-EASL…
Treatment refractory, immunologically cold, hepatic tumor type 37% reduction and 83% stabilization of treated disease (2D-EASL…
Treatment refractory, immunologically cold, hepatic tumor type 50% reduction of treated disease; 83% stabilization of overall…
Treatment refractory, immunologically cold, hepatic tumor type 50% reduction of treated disease; 83% stabilization of overall…
Treatment refractory, immunologically cold, hepatic tumor type 50% reduction of treated disease; 83% stabilization of overall…
Treatment refractory, immunologically cold, hepatic tumor type 50% reduction of treated disease; 83% stabilization of overall…
Treatment refractory, immunologically cold, hepatic tumor type 50% reduction of treated disease; 83% stabilization of overall…
KNOXVILLE, TN, May 18, 2020 ( ) - Provectus (OTCQB: PVCT) today is pleased to announce the publication of an abstract about and…
(GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today is pleased to announce the publication of an abstract about and data from…
(GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today is pleased to announce the publication of an abstract about and data from…
Discovered by Christian de Duve, MD in 1955, lysosomes are linked to several biological processes, including cell death and…
(GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today is pleased to announce the publication of an abstract about and data from…
(GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today is pleased to announce the publication of an abstract about and data from…
KNOXVILLE, TN, April 29, 2020 ( ) - Provectus (OTCQB: PVCT) today is pleased to announce that abstracts about and data from our…
(GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today is pleased to announce that abstracts about and data from our clinical trials…
(GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today is pleased to announce that abstracts about and data from our clinical trials…
KNOXVILLE, TN, April 29, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today is pleased to announce that abstracts about and…
(GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today is pleased to announce that abstracts about and data from our clinical trials…